| 1. Addendum: A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study |
Page:e63— |
| 2. Factors predicting postoperative morbidity after cytoreductive surgery for ovarian cancer: a systematic review and meta-analysis |
Page:e53— |
| 3. Quality of life outcomes from the randomized trial of hyperthermic intraperitoneal chemotherapy following cytoreductive surgery for primary ovarian cancer (KOV-HIPEC-01) |
Page:e54— |
| 4. Differences in age at diagnosis of ovarian cancer for each BRCA mutation type in Japan: optimal timing to carry out risk-reducing salpingo-oophorectomy |
Page:e46— |
| 5. Turning up the heat does not affect quality of life |
Page:e68— |
| 6. A step towards the ambition of precision oncology in recurrent ovarian cancer |
Page:e64— |
| 7. Book Review: IARC handbooks of cancer prevention, volume 18: Cervical cancer screening |
Page:e65— |
| 8. Bone health after RRBSO among BRCA1/2 mutation carriers: a population-based study |
Page:e51— |
| 9. Diagnostic performance of microRNA-34a, let-7f and microRNA-31 in epithelial ovarian cancer prediction |
Page:e49— |
| 10. TP53 variants in p53 signatures and the clonality of STICs in RRSO samples |
Page:e50— |
| 11. Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial |
Page:e45— |
| 12. Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052) |
Page:e55— |
| 13. Survival benefits of retroperitoneal lymphadenectomy for optimally-resected advanced ovarian high-grade serous carcinoma: a multi-institutional retrospective study |
Page:e40— |
| 14. Associations between obesity, metabolic syndrome, and endometrial cancer risk in East Asian women |
Page:e35— |
| 15. Trends in cervical cancer screening rates among Korean women: results of the Korean National Cancer Screening Survey, 2005–2020 |
Page:e39— |
